Overview

A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma

Status:
Withdrawn
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
This is a national, single arm, phase II trial in patients with diagnosis of unresectable or advanced malignant pleural mesothelioma who experienced progression after platinum-based chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Health Pharma Professional Research
Collaborator:
ILS Clinical Research
Treatments:
Antibodies, Monoclonal
Atezolizumab